AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 33 analysts
Fundamentals
Fundamentals institutional score is 33 using accruals ratio -0.181; growth durability 14.2.
Valuation
Valuation institutional score is 85 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 69 using mean target upside 16.7%; dispersion penalty 13.0; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 96 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. valuation and analyst consensus provide support, while fundamentals and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 4.5% below historical median. Valuation is stable — currently in the strongly undervalued zone (z-score: -0.64). Confidence: 90%.
Live forward EPS implies next-12-month EPS of ₹73.16. Applying the stock's normalized valuation corridor produces a fair range of ₹2,632.30 to ₹3,123.93, with base value near ₹2,825.44 (+53.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹73.16
Forward P/E
25.2x
Base Fair Value
₹2,825.44
Fair Range
₹2,632.30 - ₹3,123.93
Upside To Base
+53.4%
Estimate Source
Live forward EPS
Growth Estimate
-52.1%
5Y Average
37.63
Current
36.88
Overvalued
42.70
Undervalued
35.98
5Y Average
13.15
Current
12.89
Overvalued
14.39
Undervalued
12.28
5Y Average
2.14
Current
1.92
Overvalued
2.46
Undervalued
1.82
Peers & Comparison
Sector: Materials · Theme: Cement
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
AMBUJA CEMENTS LTD AMBUJACEMCement | -7.7% | 11.1% | 23.6x Undervalued | -82% vs avg | -27.0% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.2x Undervalued | -78% vs avg | -3.9% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 51.2x Undervalued | -62% vs avg | +44.4% |
MAX FINANCIAL SERV LTD MFSLInsurance | -40.2% | 0.2% | 631.7x Premium | +370% vs avg | -5.6% |
BHARAT FORGE LTD BHARATFORGIron & Steel | +18.7% | 4.0% | 140.9x Fair | +5% vs avg | +73.6% |
HERO MOTOCORP LIMITED HEROMOTOCOTwo Wheelers | +34.9% | 10.7% | 21.7x Undervalued | -84% vs avg | +23.0% |
CG POWER AND IND SOL LTD CGPOWERHeavy Electrical Equipments | +14.0% | 9.8% | 112.0x Undervalued | -17% vs avg | +31.4% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 63.8x Undervalued | -53% vs avg | +12.1% |
DALMIA BHARAT LIMITED trades at a discount (36.9x vs peer avg 134.4x), suggesting potential undervaluation relative to the Cement cohort. Peers include AMBUJA CEMENTS LTD, DR. REDDY S LABORATORIES, BSE LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹3.89K CrJun 2026Latest net profit
₹188 CrJun 2026Latest EPS
₹10.02Jun 2026Net margin
11.4%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
Sales
₹3,890 Cr
Net Profit
₹188 Cr
EBITDA
₹762 Cr
EPS
₹10.02
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 35 | 33 | 30 | 32 | 34 | 29 | 61 | 78 | 75 | 80 | 101 | 105 | 3,890 |
| Expenses | 30 | 32 | 28 | 28 | 25 | 30 | 24 | 52 | 71 | 65 | 68 | 72 | 81 | 3,446 |
| Operating Profit | 2 | 2 | 3 | 1 | 6 | 3 | 3 | 7 | 5 | 7 | 9 | 19 | 15 | 444 |
| OPM % | 5.88% | 5.71% | 9.09% | 3.33% | 18.75% | 8.82% | 10.34% | 11.48% | 6.41% | 9.33% | 11.25% | 18.81% | 14.29% | 11.41% |
| Other Income | 94 | 9 | 85 | 9 | 12 | 99 | 12 | 8 | 70 | 28 | 7 | 8 | 80 | 139 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 105 | 1 | 1 | 5 | 11 | 147 |
| Depreciation | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 10 | 9 | 361 |
| Profit before tax | 95 | 10 | 87 | 9 | 17 | 101 | 14 | 14 | 75 | 34 | 15 | 22 | 84 | 254 |
| Tax % | 6.32% | 10% | 4.6% | 0% | 35.29% | 4.95% | 28.57% | 50% | -2.67% | 2.94% | 6.67% | 13.64% | 10.71% | 24.41% |
| Net Profit | 89 | 9 | 83 | 9 | 11 | 96 | 10 | 7 | 77 | 33 | 14 | 19 | 75 | 188 |
| EPS in Rs | 4.78 | 0.50 | 4.39 | 0.50 | 0.59 | 5.13 | 0.51 | 0.38 | 0.38 | 1.76 | 0.75 | 0.75 | 1.16 | 10.02 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.
Events Timeline
Intimation Of Schedule Of Analyst/ Institutional Investor Meeting(S)
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Identification Of Company'S Subsidiary As Successful Resolution Applicant For Bhilai Jaypee Cement Limited And Issuance Of Letter Of Intent Thereof By The Resolution Professional